Peers: ABBV VRTX ALNY GILD INCY NBIX REGN BIIB BMY EXEL

| Held by: VTI IWM FNDA VXF IWO IBB XBI VTWO SCHA FESM

Index	RUT	P/E	26.97	EPS (ttm)	0.12	Insider Own	3.61%	Shs Outstand	163.06M	Perf Week	-12.16%
Market Cap	529.94M	Forward P/E	2.41	EPS next Y	1.35	Insider Trans	-54.64%	Shs Float	157.17M	Perf Month	-27.78%
Enterprise Value	912.28M	PEG	0.02	EPS next Q	0.25	Inst Own	95.23%	Short Float	8.22%	Perf Quarter	-9.22%
Income	24.02M	P/S	1.79	EPS this Y	753.33%	Inst Trans	4.41%	Short Ratio	2.91	Perf Half Y	153.91%
Sales	296.15M	P/B	-	EPS next Y	5.47%	ROA	6.42%	Short Interest	12.92M	Perf YTD	-3.56%
Book/sh	-1.61	P/C	2.46	EPS next 5Y	118.28%	ROE	-	52W High	5.78 -43.77%	Perf Year	111.04%
Cash/sh	1.32	P/FCF	4.17	EPS past 3/5Y	-46.07% -25.92%	ROIC	18.05%	52W Low	0.53 516.58%	Perf 3Y	-68.66%
Dividend Est.	-	EV/EBITDA	7.56	Sales past 3/5Y	-10.32% -5.33%	Gross Margin	99.36%	Volatility	7.81% 9.27%	Perf 5Y	-71.81%
Dividend TTM	-	EV/Sales	3.08	EPS Y/Y TTM	1233.64%	Oper. Margin	40.10%	ATR (14)	0.33	Perf 10Y	-61.93%
Dividend Ex-Date	-	Quick Ratio	1.13	Sales Y/Y TTM	-15.72%	Profit Margin	8.11%	RSI (14)	35.14	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	1.13	EPS Q/Q	-170.35%	SMA20	-11.92%	Beta	0.19	Target Price	7.88
Payout	0.00%	Debt/Eq	-	Sales Q/Q	-47.31%	SMA50	-24.01%	Rel Volume	2.34	Prev Close	3.37
Employees	100	LT Debt/Eq	-	Earnings	Feb 25 BMO	SMA200	39.90%	Avg Volume	4.44M	Price	3.25
IPO	Feb 03, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	84.62% -6.30%	Trades		Volume	10,410,264	Change	-3.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$8
Apr-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-15-25	Downgrade	Jefferies	Buy → Hold
Apr-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Sep-09-24	Initiated	Leerink Partners	Market Perform	$5
Aug-08-24	Downgrade	CapitalOne	Overweight → Equal Weight	$12 → $4
Jan-17-24	Initiated	Craig Hallum	Buy	$21
Dec-14-23	Initiated	Wells Fargo	Overweight	$20
Nov-09-23	Initiated	Jefferies	Buy	$21
Sep-28-23	Initiated	JMP Securities	Mkt Outperform	$22
Sep-02-22	Initiated	CapitalOne	Overweight	$15
Apr-22-22	Initiated	Piper Sandler	Overweight	$16
Sep-30-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$14 → $9
Jun-17-20	Initiated	Northland Capital	Outperform	$14
Jul-10-19	Resumed	Credit Suisse	Neutral
Mar-27-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-25-19	Upgrade	H.C. Wainwright	Sell → Neutral	$14
Jan-24-19	Upgrade	JP Morgan	Underweight → Neutral
Nov-07-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-18	Downgrade	Credit Suisse	Outperform → Neutral

Show Previous Ratings

Mar-06-26 08:21AM	Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? (Zacks)
Mar-04-26 04:05PM	Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference (Business Wire)
Feb-26-26 10:40AM	IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks (Zacks) +8.93%
Feb-25-26 04:03PM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2025 Earnings Call Highlights: Strong LINZESS Sales and ... (GuruFocus.com) -11.35%
03:29PM	Ironwood Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
12:35PM	Loading…
12:35PM	Ironwood Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
12:15PM	Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:28AM	Ironwood: Q4 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook (Business Wire)
Feb-23-26 09:07AM	What's in Store for These 5 Medical Companies This Earnings Season? (Zacks) -5.30%
Feb-20-26 10:57AM	Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now? (Zacks) -14.10%
Feb-18-26 04:21PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call (Business Wire)
Feb-13-26 01:11PM	Waters Q4 Earnings Surpass Estimates, Revenues Increase Y/Y (Zacks)
Feb-12-26 10:35AM	IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock? (Zacks)
Feb-08-26 08:28AM	3 Stocks Trading Near $5 With Massive Earnings Upside (MarketBeat)
08:48AM	Loading…
Feb-05-26 08:48AM	Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption? (Zacks)
Feb-04-26 09:06AM	Craig-Hallum Bullish on Ironwood Pharmaceuticals (IRWD), Keeps Buy Rating (Insider Monkey) -6.37%
Jan-26-26 02:11AM	Zacks.com featured highlights include IPG Photonics, Ironwood and Science Applications (Zacks)
Jan-23-26 10:33AM	4 Stocks Trading Near 52-Week High With More Upside Potential (Zacks)
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
Jan-07-26 03:25PM	Ironwood Pharmaceuticals' 2026 Guidance Shock Sparks a Major Re-Rating (MarketBeat) -5.12%
08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-05-26 10:28AM	Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 (Zacks) +7.49%
Jan-03-26 07:20AM	Ironwood backs FY25 revenue view $290M-$310M, consensus $306.97M (TipRanks)
07:20AM	Ironwood sees FY26 revenue $450M-$475M, consensus $319.47M (TipRanks)
Jan-02-26 12:21PM	Ironwood Pharmaceuticals Stock Soars as Drug-Price Cut Boosts Prospects for 2026 (Barrons.com) +26.71%
07:05AM	Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance (Business Wire)
Dec-10-25 11:30AM	Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report? (Zacks)
Nov-28-25 10:11AM	Ironwood (IRWD) Skyrockets 23% as Govt Price for Linzess Falls Within Expectations (Insider Monkey) -9.33%
Nov-27-25 11:58AM	IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? (Zacks)
10:30AM	Loading…
Nov-21-25 10:30AM	Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3? (Zacks)
Nov-13-25 10:36AM	IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) +8.36%
Nov-11-25 09:56AM	IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars (Zacks) +14.23%
Nov-10-25 08:25AM	Ironwood Pharmaceuticals (IRWD) Q3 Earnings and Revenues Surpass Estimates (Zacks) +31.77%
07:21AM	Ironwood: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance (Business Wire)
Nov-06-25 07:35AM	Former blockbuster Linzess grows label with paediatric IBS-C approval (Pharmaceutical Technology)
Nov-05-25 05:35PM	Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +10.16%
Oct-20-25 09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? (Zacks) +7.69%
Oct-16-25 07:56AM	BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Oct-15-25 09:17AM	Teladoc Health Expands Clarity Platform With Workplace Safety Tool (Zacks) +8.78%
06:19AM	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks)
Oct-14-25 10:57AM	5 Small Drug Stocks to Buy as the Industry Shows Some Recovery (Zacks)
09:50AM	Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term (Zacks)
Sep-22-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-21-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks) +7.27%
Aug-08-25 10:36AM	IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates (Zacks)
Aug-07-25 08:25AM	Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates (Zacks) +9.32%
07:26AM	Ironwood: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance (Business Wire)
Jun-06-25 11:31AM	Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report? (Zacks) +6.58%
May-08-25 09:55AM	IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates (Zacks) -11.63%
May-07-25 08:20AM	Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -14.55%
07:26AM	Ironwood: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports First Quarter 2025 Results (Business Wire)
May-06-25 10:00AM	Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
May-05-25 07:15AM	Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-03-25 10:24PM	The 1-Minute Market Report May 4, 2025 (Seeking Alpha)
May-01-25 10:01AM	Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-25 04:25PM	Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference (Business Wire)
Apr-28-25 10:25AM	The 1-Minute Market Report April 27, 2025 (Seeking Alpha) +9.23%
Apr-25-25 07:05AM	Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance (Business Wire)
Apr-22-25 04:05PM	Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support (Business Wire) +7.66%
Apr-16-25 01:07PM	Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News (Zacks)
Apr-15-25 09:18AM	Ironwood Shares Tank on Regulatory Update for Apraglutide (Zacks) +11.47%
07:12AM	Ironwoods shares sink as FDA demands new trial for lead drug (Pharmaceutical Technology)
Apr-14-25 07:00AM	Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide (Business Wire) -31.48%
Apr-13-25 10:44AM	The 1-Minute Market Report April 13, 2025 (Seeking Alpha)
Apr-10-25 10:49AM	Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth (Seeking Alpha)
09:25AM	Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? (Insider Monkey)
Apr-01-25 10:28AM	Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? (Zacks)
Mar-31-25 08:05AM	The 1-Minute Market Report March 30, 2025 (Seeking Alpha)
Mar-27-25 04:05PM	Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing (Business Wire)
Mar-25-25 11:08AM	Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? (Zacks)
Mar-02-25 12:24PM	Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-28-25 02:14AM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ... (GuruFocus.com)
Feb-27-25 11:20PM	Q4 2024 Ironwood Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -5.26%
08:15AM	Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates (Zacks)
07:20AM	Ironwood: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance (Business Wire)
Feb-26-25 08:13AM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-20-25 04:00PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call (Business Wire)
Feb-05-25 06:28PM	Millrose Properties Set to Join S&P SmallCap 600 (PR Newswire) -8.06%
Jan-29-25 04:05PM	Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future (Business Wire) -38.17%
Jan-18-25 08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)
Dec-20-24 09:15AM	Heres Why Brown Capital Management Small Company Fund Sold Ironwood Pharmaceuticals (IRWD) (Insider Monkey) +14.69%
Nov-26-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +5.07%
Nov-13-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-08-24 04:01AM	Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com) +6.44%
Nov-07-24 08:15AM	Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates (Zacks) -7.54%
07:20AM	Ironwood: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Third Quarter 2024 Results (Business Wire)
Nov-06-24 07:29AM	Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com) +12.25%
Oct-28-24 07:00AM	Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024 (Business Wire)
Oct-24-24 04:00PM	Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call (Business Wire)
Oct-16-24 01:06PM	State Street Corp's Strategic Acquisition of Ironwood Pharmaceuticals Shares (GuruFocus.com)
08:58AM	Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts? (Insider Monkey)
Oct-09-24 05:36PM	Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ... (GuruFocus.com)
Sep-17-24 08:40AM	Implied Volatility Surging for Ironwood (IRWD) Stock Options (Zacks)
Sep-01-24 10:26PM	Ironwood Pharmaceuticals, Inc. (IRWD): The Best Multibagger Penny Stock of 2025? (Insider Monkey)

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DENNER ALEXANDER J	Director	Mar 17 '26	Sale	3.05	6,730,800	20,530,448	9,188,635	Mar 17 08:34 PM
John Minardo	Chief Legal Officer	Feb 24 '26	Sale	3.66	19,053	69,734	363,886	Feb 25 04:05 PM
John Minardo	Chief Legal Officer	Feb 23 '26	Sale	3.81	17,439	66,443	382,939	Feb 25 04:05 PM
Shetzline Michael	SVP, CMO, Head-Res&Drug	Feb 23 '26	Sale	3.81	15,570	59,322	538,437	Feb 25 04:05 PM
Gaskins Tammi L	Chief Commercial Officer	Feb 24 '26	Sale	3.66	11,239	41,135	213,738	Feb 25 04:05 PM
Gaskins Tammi L	Chief Commercial Officer	Feb 23 '26	Sale	3.81	10,287	39,193	224,977	Feb 25 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Feb 24 '26	Sale	3.66	103,526	378,905	1,489,002	Feb 25 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Feb 23 '26	Sale	3.81	94,757	361,024	1,592,528	Feb 25 04:05 PM
Martini Gregory S.	Chief Financial Officer	Feb 24 '26	Sale	3.66	11,457	41,933	160,601	Feb 25 04:05 PM
Martini Gregory S.	Chief Financial Officer	Feb 23 '26	Sale	3.81	10,487	39,955	172,058	Feb 25 04:05 PM
Silver Ronald	Principal Accounting Officer	Feb 24 '26	Sale	3.66	12,621	46,193	252,636	Feb 25 04:05 PM
Silver Ronald	Principal Accounting Officer	Feb 23 '26	Sale	3.81	11,552	44,013	265,257	Feb 25 04:05 PM
Gaskins Tammi L	Officer	Feb 23 '26	Proposed Sale	4.61	19,775	91,163		Feb 20 04:46 PM
Martini Gregory S.	Officer	Feb 23 '26	Proposed Sale	4.61	20,163	92,951		Feb 20 04:45 PM
Shetzline Michael	Officer	Feb 23 '26	Proposed Sale	4.61	29,937	138,010		Feb 20 04:44 PM
John Minardo	Officer	Feb 23 '26	Proposed Sale	4.61	33,528	154,564		Feb 20 04:42 PM
MCCOURT Thomas A	Officer	Feb 23 '26	Proposed Sale	4.61	182,185	839,873		Feb 20 04:41 PM
Silver Ronald	Principal Accounting Officer	Jan 05 '26	Sale	4.60	35,416	162,914	276,809	Jan 07 04:05 PM
RONALD SILVER	Officer	Jan 05 '26	Proposed Sale	4.27	35,416	151,226		Jan 05 04:41 PM
Gaskins Tammi L	Chief Commercial Officer	Nov 17 '25	Sale	3.32	6,016	19,973	235,264	Nov 19 04:05 PM
Gaskins Tammi L	Officer	Nov 17 '25	Proposed Sale	3.37	6,324	21,312		Nov 14 04:05 PM
Gaskins Tammi L	Chief Commercial Officer	Aug 11 '25	Sale	0.84	1,316	1,105	241,280	Aug 13 04:05 PM
John Minardo	Chief Legal Officer	Aug 11 '25	Sale	0.84	7,754	6,513	400,378	Aug 13 04:05 PM
Martini Gregory S.	Chief Financial Officer	Aug 11 '25	Sale	0.84	1,265	1,063	182,545	Aug 13 04:05 PM
Silver Ronald	Principal Accounting Officer	Aug 11 '25	Sale	0.84	2,846	2,391	276,809	Aug 13 04:05 PM
John Minardo	Officer	Aug 11 '25	Proposed Sale	0.88	8,281	7,287		Aug 08 04:10 PM
Martini Gregory S.	Officer	Aug 11 '25	Proposed Sale	0.88	1,351	1,189		Aug 08 04:09 PM
Gaskins Tammi L	Officer	Aug 11 '25	Proposed Sale	0.88	1,406	1,237		Aug 08 04:08 PM
MCCOURT Thomas A	Chief Executive Officer	May 16 '25	Sale	0.58	13,353	7,745	1,147,281	May 20 04:14 PM
Gaskins Tammi L	Chief Commercial Officer	May 16 '25	Sale	0.58	2,563	1,487	242,596	May 20 04:10 PM
MCCOURT Thomas A	Officer	May 19 '25	Proposed Sale	0.59	14,661	8,650		May 16 04:07 PM
Gaskins Tammi L	Officer	May 19 '25	Proposed Sale	0.59	2,814	1,660		May 16 04:05 PM

Open in Screener

INVA

Innoviva Inc

Mar 17 • 04:00PM ET

22.06

-0.09 -0.41 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD MRK ABBV AMGN REGN BIIB BMY VRTX PFE SAN

| Held by: IJR VTI VB AVUV IWM VBR VXF SPSM DFAT PJP

Index	RUT	P/E	7.22	EPS (ttm)	3.06	Insider Own	1.16%	Shs Outstand	74.64M	Perf Week	-1.56%
Market Cap	1.63B	Forward P/E	9.98	EPS next Y	2.21	Insider Trans	0.00%	Shs Float	73.21M	Perf Month	-2.82%
Enterprise Value	1.34B	PEG	-	EPS next Q	0.39	Inst Own	102.59%	Short Float	9.10%	Perf Quarter	6.93%
Income	271.17M	P/S	3.84	EPS this Y	-42.00%	Inst Trans	0.05%	Short Ratio	8.42	Perf Half Y	12.84%
Sales	425.13M	P/B	1.40	EPS next Y	15.46%	ROA	18.26%	Short Interest	6.66M	Perf YTD	10.36%
Book/sh	15.71	P/C	2.88	EPS next 5Y	-15.37%	ROE	29.09%	52W High	25.15 -12.27%	Perf Year	25.84%
Cash/sh	7.65	P/FCF	8.35	EPS past 3/5Y	- 10.35%	ROIC	18.81%	52W Low	16.52 33.54%	Perf 3Y	97.32%
Dividend Est.	-	EV/EBITDA	6.55	Sales past 3/5Y	325.77% 3.93%	Gross Margin	72.33%	Volatility	1.87% 2.95%	Perf 5Y	79.79%
Dividend TTM	-	EV/Sales	3.14	EPS Y/Y TTM	924.98%	Oper. Margin	38.52%	ATR (14)	0.63	Perf 10Y	97.67%
Dividend Ex-Date	Sep 08, 2015	Quick Ratio	13.85	Sales Y/Y TTM	14.12%	Profit Margin	63.78%	RSI (14)	47.68	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	14.64	EPS Q/Q	587.65%	SMA20	-3.18%	Beta	0.43	Target Price	33.20
Payout	0.00%	Debt/Eq	0.23	Sales Q/Q	23.95%	SMA50	3.04%	Rel Volume	0.56	Prev Close	22.15
Employees	159	LT Debt/Eq	0.23	Earnings	Feb 25 AMC	SMA200	9.55%	Avg Volume	791.06K	Price	22.06
IPO	Oct 05, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	252.09% 11.68%	Trades		Volume	442,309	Change	-0.41%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-17-26	Initiated	BTIG Research	Buy	$35
Sep-30-25	Initiated	Goldman	Sell	$17
Aug-11-25	Initiated	Oppenheimer	Outperform	$45
Jul-14-25	Initiated	H.C. Wainwright	Buy	$40
Jul-11-25	Initiated	Cantor Fitzgerald	Overweight	$26
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$55
Jun-18-24	Initiated	Cantor Fitzgerald	Overweight
Jul-20-22	Initiated	Goldman	Neutral	$16
Nov-20-17	Initiated	Deutsche Bank	Hold	$13

Mar-01-26 04:27AM	Cantor Fitzgerald Lifts PT on Innoviva, Inc. (INVA) to $32 from $31 - Here's Why (Insider Monkey)
Feb-28-26 08:26AM	Innoviva, Inc. (INVA): A Bull Case Theory (Insider Monkey)
06:45AM	Innoviva CEO Details 3-Part Growth Plan, $125M Buyback, and 2026 Catalysts at Oppenheimer Conference (MarketBeat)
Feb-26-26 01:48PM	Celldex Therapeutics Stock Earns 88 RS Rating (Investor's Business Daily)
Feb-25-26 08:17PM	Nurix Therapeutics Stock Sees RS Rating Jump To 82 (Investor's Business Daily)
05:08PM	Loading…
05:08PM	Innoviva: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Feb-24-26 01:14PM	CRISPR Therapeutics Stock Sees RS Rating Rise To 73 (Investor's Business Daily)
01:02PM	Xenon Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Feb-19-26 08:21AM	AtaiBeckley names Michael Faerm as finance chief (Proactive)
08:00AM	Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference (Business Wire)
Feb-18-26 09:17AM	Bayer (BAYRY) Surges 6.0%: Is This an Indication of Further Gains? (Zacks)
Feb-04-26 07:55AM	Eli Lilly (LLY) Q4 Earnings and Revenues Beat Estimates (Zacks)
Jan-08-26 08:23AM	Biotech Is Heating Up-These 2 Red-Hot Stocks Stand Out (MarketBeat)
Dec-21-25 09:57AM	H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating (Insider Monkey)
04:56PM	Loading…
Dec-12-25 04:56PM	U.S. FDA Approves NUZOLVENCE (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents (Business Wire)
Dec-11-25 06:35PM	Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea (Business Wire)
Nov-25-25 07:00AM	Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-14-25 04:47AM	Beacon Biosignals secures $86m to advance AI-driven brain biomarker use (Medical Device Network)
Nov-05-25 06:40PM	Innoviva (INVA) Q3 Earnings and Revenues Beat Estimates (Zacks) +12.89%
05:33PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Nov-04-25 08:00AM	Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-31-25 09:00AM	AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-30-25 07:55AM	Eli Lilly (LLY) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-23-25 05:02AM	Strength Seen in Innoviva (INVA): Can Its 5.5% Jump Turn into More Strength? (Zacks)
Oct-21-25 08:00AM	Antheia Appoints Eric d'Esparbes as Chief Financial Officer (PR Newswire)
Oct-20-25 08:00AM	Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025 (Business Wire)
Oct-14-25 07:30AM	Johnson & Johnson (JNJ) Beats Q3 Earnings and Revenue Estimates (Zacks)
Oct-10-25 06:21AM	New Strong Buy Stocks for October 10th (Zacks)
09:40AM	Loading…
Oct-07-25 09:40AM	Are Investors Undervaluing Innoviva (INVA) Right Now? (Zacks)
08:00AM	Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025 (Business Wire)
Sep-17-25 02:27PM	Where is Innoviva (INVA) Headed According to Analysts? (Insider Monkey)
Aug-26-25 07:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
Aug-13-25 08:00AM	Innoviva Specialty Therapeutics Antimicrobial Therapies ZEVTERA and XACDURO Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award (Business Wire)
Aug-12-25 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update (PR Newswire)
Aug-11-25 09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly) +7.14%
Aug-06-25 05:06PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Jun-12-25 07:00AM	FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 (Business Wire)
Jun-10-25 06:00AM	Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults (Business Wire)
Jun-03-25 07:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
May-20-25 06:00AM	ZEVTERA (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections (Business Wire)
May-08-25 08:54AM	Innoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are Selling (Insider Monkey)
May-07-25 05:52PM	Innoviva: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Apr-11-25 12:30AM	Harbor Health Care ETF Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 06:35PM	Victorias Secret, Bitdeer, and More Stocks See Activist Action (Barrons.com)
Mar-14-25 06:17PM	WEX, Lamb Weston, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-12-25 05:08PM	Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva (PR Newswire)
Mar-05-25 07:00AM	Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference (Business Wire)
Feb-26-25 04:35PM	Innoviva: Q4 Earnings Snapshot (Associated Press Finance)
04:04PM	Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Feb-06-25 07:00AM	Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-17-24 07:25AM	Innoviva enters distribution, license agreement with Basilea for Zevtera (TipRanks)
Dec-16-24 07:00AM	Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera (ceftobiprole) (Business Wire)
01:15AM	Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera (ceftobiprole) in the United States (GlobeNewswire)
Nov-26-24 07:00AM	Innoviva to Participate in the Citi 2024 Global Healthcare Conference (Business Wire)
Nov-21-24 11:14PM	Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity (PR Newswire)
Nov-12-24 04:05PM	Innoviva to Participate in the UBS Global Healthcare Conference (Business Wire)
Nov-06-24 05:23PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Sep-04-24 07:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
Jul-31-24 10:54PM	INVA Stock Earnings: Innoviva Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:51PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Jul-09-24 01:30PM	The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024 (InvestorPlace)
Jun-27-24 08:00AM	3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge (InvestorPlace)
Jun-18-24 09:51AM	Apple downgraded, Kroger upgraded: Wall Street's top analyst calls (The Fly)
Jun-03-24 07:00AM	Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-31-24 07:30AM	3 Under-$20 Stocks That Could Make You a Fortune (InvestorPlace)
May-20-24 04:06AM	Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment (MT Newswires)
May-10-24 02:04PM	Innoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed Analysis (GuruFocus.com)
May-08-24 10:57PM	INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:09PM	Innoviva: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
07:00AM	Innoviva to Participate in the BofA Securities Health Care Conference (Business Wire)
Apr-24-24 07:00AM	Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 (Business Wire)
Mar-04-24 04:01PM	Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva (PR Newswire)
Feb-29-24 04:56PM	Innoviva: Q4 Earnings Snapshot (Associated Press Finance)
04:37PM	Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress (Business Wire)
Feb-14-24 02:44AM	Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition (GuruFocus.com)
Jan-10-24 06:16PM	If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names (InvestorPlace)
Nov-18-23 07:03AM	Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc (GuruFocus.com)
Nov-03-23 06:00AM	Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million (GuruFocus.com)
Nov-01-23 05:32PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance) +6.92%
04:15PM	Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
04:05PM	Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea (Business Wire)
Sep-19-23 08:30AM	Innoviva to Participate in the Cantor Global Healthcare Conference (Business Wire)
Sep-18-23 08:00AM	XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults (Business Wire)
Aug-25-23 04:52PM	Innoviva Appoints Stephen Basso as Chief Financial Officer (Business Wire)
Aug-02-23 05:18PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Jul-23-23 09:22AM	Investors in Innoviva (NASDAQ:INVA) have unfortunately lost 11% over the last year (Simply Wall St.)
Jul-11-23 08:53PM	Why These 7 Stocks Are the Best Ways to Play Biotech Right Now (InvestorPlace)
08:00AM	Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics (PR Newswire)
Jul-06-23 11:33AM	12 Best Extremely Profitable Stocks to Buy (Insider Monkey)
Jun-26-23 01:27AM	Insider trades & hedge fund hits: Elliott aims to oust NRG chief (Investing.com)
Jun-21-23 08:00PM	INVA: What does Argus have to say about INVA? (Argus Research)

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

IRWD

Ironwood Pharmaceuticals Inc

INVA

Innoviva Inc

Upgrade your FINVIZ experience